HRP20041060B1 - (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker - Google Patents
(imidazol-1-yl-methyl)-pyridazine as nmda receptor blockerInfo
- Publication number
- HRP20041060B1 HRP20041060B1 HRP20041060A HRP20041060B1 HR P20041060 B1 HRP20041060 B1 HR P20041060B1 HR P20041060 A HRP20041060 A HR P20041060A HR P20041060 B1 HRP20041060 B1 HR P20041060B1
- Authority
- HR
- Croatia
- Prior art keywords
- pyridazine
- imidazol
- methyl
- nmda receptor
- receptor blocker
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Addiction (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02010217 | 2002-05-16 | ||
| PCT/EP2003/005151 WO2003097637A1 (fr) | 2002-05-16 | 2003-05-16 | (imidazol-1-yl-methyl)-pyridazine en tant qu'antagoniste du recepteur nmda |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20041060A2 HRP20041060A2 (en) | 2005-06-30 |
| HRP20041060B1 true HRP20041060B1 (en) | 2012-11-30 |
Family
ID=29433072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20041060 HRP20041060B1 (en) | 2002-05-16 | 2003-05-16 | (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7005432B2 (fr) |
| EP (1) | EP1506190B1 (fr) |
| JP (1) | JP4267569B2 (fr) |
| KR (1) | KR100632868B1 (fr) |
| CN (1) | CN1312151C (fr) |
| AR (1) | AR040010A1 (fr) |
| AT (1) | ATE329912T1 (fr) |
| AU (1) | AU2003242542B2 (fr) |
| BR (1) | BR0311177A (fr) |
| CA (1) | CA2485926C (fr) |
| CL (1) | CL2004001251A1 (fr) |
| CY (1) | CY1105159T1 (fr) |
| DE (1) | DE60306152T2 (fr) |
| DK (1) | DK1506190T3 (fr) |
| ES (1) | ES2265581T3 (fr) |
| HR (1) | HRP20041060B1 (fr) |
| IL (1) | IL164922A (fr) |
| MA (1) | MA27117A1 (fr) |
| ME (1) | MEP76708A (fr) |
| MX (1) | MXPA04011253A (fr) |
| NO (1) | NO329605B1 (fr) |
| NZ (1) | NZ536310A (fr) |
| PL (1) | PL211340B1 (fr) |
| PT (1) | PT1506190E (fr) |
| RS (1) | RS51200B (fr) |
| RU (1) | RU2317294C2 (fr) |
| SI (1) | SI1506190T1 (fr) |
| TN (1) | TNSN04224A1 (fr) |
| WO (1) | WO2003097637A1 (fr) |
| ZA (1) | ZA200408789B (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| CN100579579C (zh) * | 2002-10-01 | 2010-01-13 | 诺华疫苗和诊断公司 | 抗癌及抗感染性疾病组合物及其使用方法 |
| CN103204996B (zh) | 2005-05-03 | 2015-12-09 | 默克专利有限公司 | 有机电致发光器件 |
| US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| JP5315710B2 (ja) * | 2008-02-07 | 2013-10-16 | セントラル硝子株式会社 | １−ブロモ−３−フルオロ−５−ジフルオロメチルベンゼンの製造方法 |
| DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
| CA2719749A1 (fr) * | 2008-03-27 | 2009-10-01 | Evotec Neurosciences Gmbh | Procedes pour traiter des troubles utilisant un antagoniste selectif de sous-type nr2b de nmda |
| SI2393360T1 (sl) | 2009-02-05 | 2016-02-29 | Takeda Pharmaceutical Company Limited | Piridazinonske spojine |
| EP2602255B1 (fr) * | 2010-08-04 | 2017-04-26 | Takeda Pharmaceutical Company Limited | Composé à cycle hétérocyclique fusionné |
| WO2012019106A2 (fr) * | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Modulateurs positifs et négatifs des récepteurs nmda |
| WO2013160728A1 (fr) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Composés à double ciblage pour le traitement de la maladie d'alzheimer |
| HUE049277T2 (hu) * | 2014-08-15 | 2020-09-28 | Janssen Pharmaceuticals Inc | Triazolok mint NR2B receptor inhibitorok |
| DE102015011861B4 (de) | 2015-09-10 | 2018-03-01 | Rudolf Schindler | Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren |
| HRP20201522T1 (hr) | 2015-12-09 | 2020-12-11 | Cadent Therapeutics, Inc. | Heteroaromatski nmda receptor modulatori i njihove uporabe |
| SG11201806750WA (en) | 2016-02-10 | 2018-09-27 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
| MX2018009857A (es) | 2016-02-18 | 2018-11-09 | Syngenta Participations Ag | Derivados de pirazol pesticidicamente activos. |
| WO2017158147A1 (fr) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Dérivés de pyrimidone et leur utilisation pour le traitement, la prévention ou l'atténuation des symptômes d'une maladie virale |
| WO2017158151A1 (fr) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Dérivés de pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| WO2018119374A1 (fr) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics | Modulateurs des récepteurs nmda et utilisations de ceux-ci |
| US11008302B2 (en) | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
| AR115905A1 (es) | 2018-08-03 | 2021-03-10 | Cadent Therapeutics Inc | 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| MX2021015500A (es) | 2019-06-14 | 2022-02-10 | Janssen Pharmaceutica Nv | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| SG11202112407PA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| JOP20210330A1 (ar) | 2019-06-14 | 2023-01-30 | Janssen Pharmaceutica Nv | مركبات بيرازولو-بيريدين عطرية غير متجانسة مستبدلة واستخدامها كمعدِّلات لمستقبل الغلوتومات "glun2b" |
| KR20220020916A (ko) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | GluN2B 수용체 조절제로서의 피리딘 카르바메이트 및 이들의 용도 |
| US11459336B2 (en) | 2019-06-14 | 2022-10-04 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| CN114478210A (zh) * | 2022-02-26 | 2022-05-13 | 江苏壹药新材料有限公司 | 一种7-氯萘-2-甲醛的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4010797A1 (de) * | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
| CA2248134A1 (fr) * | 1996-03-08 | 1997-09-12 | Anne Bourson | Utilisation de derives de 4-phenyl-3,6-dihydro-2h-pyridile comme agents bloquants des sous-types des recepteurs nmda |
| CA2220649C (fr) * | 1996-12-03 | 2007-02-13 | F. Hoffmann-La Roche Ag | Derives de 4-hydroxy-piperidine |
| US6015824A (en) | 1998-02-10 | 2000-01-18 | Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders |
| TWI254043B (en) * | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
| PT1070708E (pt) * | 1999-07-21 | 2004-05-31 | Hoffmann La Roche | Derivados de triazol |
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| ATE274494T1 (de) * | 2000-04-20 | 2004-09-15 | Hoffmann La Roche | Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen |
| US6432985B2 (en) * | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
| WO2002028814A2 (fr) | 2000-10-06 | 2002-04-11 | Regents Of The University Of California | Bloqueur de canal de recepteur nmda a activite neuroprotectrice |
| CA2381630A1 (fr) | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Methode de prevention de la dyskinesie |
| DE10120159A1 (de) | 2001-04-25 | 2002-10-31 | Merck Patent Gmbh | NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
-
2003
- 2003-05-09 US US10/434,955 patent/US7005432B2/en not_active Expired - Fee Related
- 2003-05-15 AR ARP030101685A patent/AR040010A1/es active IP Right Grant
- 2003-05-16 AU AU2003242542A patent/AU2003242542B2/en not_active Ceased
- 2003-05-16 CA CA002485926A patent/CA2485926C/fr not_active Expired - Fee Related
- 2003-05-16 RU RU2004136979/04A patent/RU2317294C2/ru not_active IP Right Cessation
- 2003-05-16 DK DK03752750T patent/DK1506190T3/da active
- 2003-05-16 EP EP03752750A patent/EP1506190B1/fr not_active Expired - Lifetime
- 2003-05-16 NZ NZ536310A patent/NZ536310A/en not_active IP Right Cessation
- 2003-05-16 CN CNB038111926A patent/CN1312151C/zh not_active Expired - Fee Related
- 2003-05-16 ES ES03752750T patent/ES2265581T3/es not_active Expired - Lifetime
- 2003-05-16 PL PL374224A patent/PL211340B1/pl unknown
- 2003-05-16 SI SI200330332T patent/SI1506190T1/sl unknown
- 2003-05-16 HR HR20041060 patent/HRP20041060B1/xx not_active IP Right Cessation
- 2003-05-16 DE DE60306152T patent/DE60306152T2/de not_active Expired - Lifetime
- 2003-05-16 KR KR1020047018485A patent/KR100632868B1/ko not_active Expired - Fee Related
- 2003-05-16 PT PT03752750T patent/PT1506190E/pt unknown
- 2003-05-16 ME MEP-767/08A patent/MEP76708A/xx unknown
- 2003-05-16 WO PCT/EP2003/005151 patent/WO2003097637A1/fr active IP Right Grant
- 2003-05-16 BR BR0311177-6A patent/BR0311177A/pt not_active IP Right Cessation
- 2003-05-16 RS YUP-985/04A patent/RS51200B/sr unknown
- 2003-05-16 AT AT03752750T patent/ATE329912T1/de active
- 2003-05-16 JP JP2004505370A patent/JP4267569B2/ja not_active Expired - Fee Related
- 2003-05-16 MX MXPA04011253A patent/MXPA04011253A/es active IP Right Grant
-
2004
- 2004-05-24 CL CL200401251A patent/CL2004001251A1/es unknown
- 2004-10-28 NO NO20044666A patent/NO329605B1/no not_active IP Right Cessation
- 2004-10-28 IL IL164922A patent/IL164922A/en not_active IP Right Cessation
- 2004-10-29 ZA ZA2004/08789A patent/ZA200408789B/en unknown
- 2004-11-11 TN TNP2004000224A patent/TNSN04224A1/fr unknown
- 2004-11-12 MA MA27943A patent/MA27117A1/fr unknown
-
2006
- 2006-08-22 CY CY20061101161T patent/CY1105159T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20041060A2 (en) | (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker | |
| PL379420A1 (pl) | Pochodne blokerów receptora angiotensyny II | |
| PL376057A1 (en) | Diaryl ethers as opioid receptor antagonist | |
| IL198122A0 (en) | Triazole derivatives as tachykinin receptor antagonists | |
| AU2002353081A1 (en) | Pulsatile release histamine h2 antagonist dosage forms | |
| AU2003257172A1 (en) | Cannabinoid receptor ligands | |
| AU2003257032A1 (en) | Antibodies against c3a receptor | |
| AP2006003840A0 (en) | Indole-2-carboxamidine derivatives as NMDA receptor antagonists | |
| PL1636206T3 (pl) | Pochodne imidazolu jako antagoniści receptorów glutaminianu | |
| AU2003248356A1 (en) | Beta3-adrenergic receptor agonists | |
| AU2003294449A1 (en) | Cannabinoid receptor ligands | |
| AU2003278403A1 (en) | 1-alkylpiperazinyl-pyrrolidin-2, 5-dione derivatives as adrenergic receptor antagonist | |
| AU2003302405A8 (en) | T-cell receptors | |
| GB0215389D0 (en) | Receptor | |
| AU2003281525A1 (en) | Serotonin receptor | |
| AU2003240730A1 (en) | Morpholinylmethylureas ccr-3 receptor antagonist | |
| GB0321998D0 (en) | Receptor | |
| AU2003236673A1 (en) | G protein-coupled receptor variants | |
| HK1084298A (en) | Receptor | |
| AUPS283002A0 (en) | Receptor | |
| AU2002338040A1 (en) | Receptor antagonist | |
| GB0329104D0 (en) | Receptor | |
| GB0307100D0 (en) | Receptor | |
| AU2002951108A0 (en) | Receptor specific ligands | |
| AU2002305947A1 (en) | Piperidine-piperazine ligand for neurotransmitter receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| PPPP | Transfer of rights |
Owner name: EVOTEC INTERNATIONAL GMBH, DE |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20140508 Year of fee payment: 12 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20150516 |